Abstract
A review on different vitamin K1-3 effects on hepatocellular cancer and their tumour cell biology mechanism indicate possible synergistic treatment strategies. Monitoring of dysfunctional carboxylation of the vitamin K dependent coagulation factor II, with the commercial ELISA test PIVKA-II has been used as a hepatocellular cancer marker. Its relevance is also reviewed. Currently the PIVKA-II test has been withdrawn due to marketing reasons by Stago
Original language | English |
---|---|
Pages (from-to) | 049-052 |
Journal | Archives of Hepatitis Research |
Volume | 3 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2017 |
Subject classification (UKÄ)
- Cancer and Oncology